摘要
目的:阐明软肝缩脾丸对肝纤维化大鼠肝脏胶原基因调节及蛋白表达的影响,探索肝纤维化发生的分子生物学机理。方法:采用免疫组化和原位杂交技术分别测定各组肝纤维大鼠治疗前后肝脏Ⅰ、Ⅲ型胶原的基因调节和蛋白表达。结果:CCl_4模型组大鼠肝脏Ⅰ、Ⅲ型胶原mRNA及蛋白水平明显高于治疗组。正常组大鼠肝组织无1例阳性。结论:软肝缩脾丸治疗可显著降低肝纤维化大鼠肝脏Ⅰ、Ⅲ型胶原的基因和蛋白表达,从而发挥其抗肝纤维化作用。
Objective: To investigate the effect of Ruangan Suopipill on hepatic fibrosis and the molecular biology mechanism of hepatic fibrosis by focusing on the expression of Ⅰ、 Ⅲ collagen which participate in the degradation of the extracellular matrix including the basement membrane. Method: Normal and hepatic fibrosis liver samples were obtained from CCl1 damaged rats underwent Ruangan Suopi Pill treatment. Transcripts for collagen Ⅰ and collagen Ⅲ or im-munohistochemical examinations were detected in the liver tissues. Results: The expression of collagen Ⅰand collagen Ⅲ mRNA in CCl4 models was significantly higher than in treatment group, and immunohistochemical examinations revealed that collagen Ⅰ and Ⅲ immunoreactivity was the most intense in the CCl4 models. Conclousion: The study showed that collagen Ⅰ and collagen Ⅲ are closely participated in hepatic tibrosis in rats. Ruangan Suopi Pill can downregulate the expression of collagen Ⅰ and collagen Ⅲ .
出处
《中西医结合肝病杂志》
CAS
2001年第3期152-153,156,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
河南省科委科研基金资助项目(No:96031)
